|
2016-02-23 |
2016-02-19 |
A
Achat
|
Flynn James E
Actionnaire important
|
21 150
+17.2%
416,56
4 769 148 $US
|
21 150
+17.2%
|
416,56
|
4 769 148 $US
|
|
|
2016-02-23 |
2016-02-19 |
A
Achat
|
Flynn James E
Actionnaire important
|
27 761
-46.8%
377,94
3 116 488 $US
|
27 761
-46.8%
|
377,94
|
3 116 488 $US
|
|
|
2016-02-16 |
2016-02-12 |
A
Achat
|
Flynn James E
Actionnaire important
|
30 609
+45.5%
295,99
4 354 690 $US
|
30 609
+45.5%
|
295,99
|
4 354 690 $US
|
|
|
2016-02-16 |
2016-02-12 |
A
Achat
|
Flynn James E
Actionnaire important
|
15 499
+0.7%
3,92
60 803 $US
|
15 499
+0.7%
|
3,92
|
60 803 $US
|
|
|
2016-02-16 |
2016-02-11 |
A
Achat
|
Flynn James E
Actionnaire important
|
1 157 189
+74.3%
3,76
4 349 642 $US
|
1 157 189
+74.3%
|
3,76
|
4 349 642 $US
|
|
|
2016-02-16 |
2016-02-11 |
A
Achat
|
Flynn James E
Actionnaire important
|
909 221
+74.3%
3,76
3 417 580 $US
|
909 221
+74.3%
|
3,76
|
3 417 580 $US
|
|
|
2016-02-16 |
2016-02-11 |
A
Achat
|
Flynn James E
Actionnaire important
|
1 557 991
+inf%
3,96
6 166 840 $US
|
1 557 991
+inf%
|
3,96
|
6 166 840 $US
|
|
|
2016-02-16 |
2016-02-11 |
A
Achat
|
Flynn James E
Actionnaire important
|
1 224 136
+inf%
3,96
4 845 375 $US
|
1 224 136
+inf%
|
3,96
|
4 845 375 $US
|
|
|
2016-01-22 |
2016-01-20 |
A
Achat
|
Flynn James E
Actionnaire important
|
346 417
+5.5%
4,09
1 418 404 $US
|
346 417
+5.5%
|
4,09
|
1 418 404 $US
|
|
|
2015-11-13 |
2015-11-11 |
V
Vente
|
Freund John Gordon
Administrateur non-exécutif
|
909
-0.2%
6,68
6 074 $US
|
909
-0.2%
|
6,68
|
6 074 $US
|
|
|
2015-07-15 |
2015-07-15 |
PlS
Vente planifiée
|
Barrett Ronald W
Chief Executive Officer
Administrateur exécutif
|
12 500
-5.8%
7,20
90 000 $US
|
12 500
-5.8%
|
7,20
|
90 000 $US
|
|
|
2015-05-12 |
2015-05-11 |
A
Achat
|
WIERENGA WENDALL
Administrateur non-exécutif
|
5 000
+20.8%
5,63
28 169 $US
|
5 000
+20.8%
|
5,63
|
28 169 $US
|
|
|
2014-12-12 |
2014-12-10 |
V
Vente
|
RIEFLIN WILLIAM JL
Administrateur non-exécutif
|
2 500
-10.3%
8,49
21 225 $US
|
2 500
-10.3%
|
8,49
|
21 225 $US
|
|
|
2014-12-12 |
2014-12-10 |
V
Vente
|
RIEFLIN WILLIAM JL
Administrateur non-exécutif
|
5 592
-18.8%
8,49
47 476 $US
|
5 592
-18.8%
|
8,49
|
47 476 $US
|
|
|
2014-12-12 |
2014-12-10 |
V
Vente
|
RIEFLIN WILLIAM JL
Administrateur non-exécutif
|
2 918
-8.9%
8,49
24 774 $US
|
2 918
-8.9%
|
8,49
|
24 774 $US
|
|
|
2014-12-10 |
2014-12-08 |
V
Vente
|
Barrett Ronald W
Chief Executive Officer
Administrateur exécutif
|
3 000
-1.8%
8,40
25 200 $US
|
3 000
-1.8%
|
8,40
|
25 200 $US
|
|
|
2014-12-10 |
2014-12-08 |
V
Vente
|
Barrett Ronald W
Chief Executive Officer
Administrateur exécutif
|
2 000
-1.2%
8,35
16 700 $US
|
2 000
-1.2%
|
8,35
|
16 700 $US
|
|
|
2014-12-10 |
2014-12-08 |
V
Vente
|
Barrett Ronald W
Chief Executive Officer
Administrateur exécutif
|
1 015
-0.6%
8,32
8 445 $US
|
1 015
-0.6%
|
8,32
|
8 445 $US
|
|
|
2014-12-10 |
2014-12-08 |
V
Vente
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Dirigeant
|
9 581
-31.6%
8,35
80 001 $US
|
9 581
-31.6%
|
8,35
|
80 001 $US
|
|
|
2014-12-10 |
2014-12-08 |
V
Vente
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Dirigeant
|
4 585
-18.1%
8,35
38 285 $US
|
4 585
-18.1%
|
8,35
|
38 285 $US
|
|
|
2014-12-10 |
2014-12-08 |
V
Vente
|
Barrett Ronald W
Chief Executive Officer
Administrateur exécutif
|
1 000
-0.6%
8,30
8 303 $US
|
1 000
-0.6%
|
8,30
|
8 303 $US
|
|
|
2014-12-08 |
2014-12-05 |
V
Vente
|
Bosko Gianna M
SVP, CLO and Secretary
Dirigeant
|
20 000
-20.6%
8,40
168 000 $US
|
20 000
-20.6%
|
8,40
|
168 000 $US
|
|
|
2014-12-08 |
2014-12-05 |
V
Vente
|
Bosko Gianna M
SVP, CLO and Secretary
Dirigeant
|
21 348
-21.7%
8,45
180 418 $US
|
21 348
-21.7%
|
8,45
|
180 418 $US
|
|
|
2014-12-08 |
2014-12-04 |
V
Vente
|
Bosko Gianna M
SVP, CLO and Secretary
Dirigeant
|
7 399
-8.8%
8,50
62 897 $US
|
7 399
-8.8%
|
8,50
|
62 897 $US
|
|
|
2014-12-08 |
2014-12-04 |
V
Vente
|
Bosko Gianna M
SVP, CLO and Secretary
Dirigeant
|
11 253
-12.7%
8,50
95 658 $US
|
11 253
-12.7%
|
8,50
|
95 658 $US
|
|
|
2014-09-10 |
2014-09-09 |
V
Vente
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Dirigeant
|
5 612
-21.3%
5,26
29 519 $US
|
5 612
-21.3%
|
5,26
|
29 519 $US
|
|
|
2014-06-04 |
2014-06-03 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
12 500
+123.4%
3,93
49 164 $US
|
12 500
+123.4%
|
3,93
|
49 164 $US
|
|
|
2014-05-27 |
2014-05-27 |
A
Achat
|
FRIEDMAN CATHY
Administrateur non-exécutif
|
2 600
+inf%
3,92
10 179 $US
|
2 600
+inf%
|
3,92
|
10 179 $US
|
|
|
2014-05-27 |
2014-05-27 |
A
Achat
|
WIERENGA WENDALL
Administrateur non-exécutif
|
10 000
+71.4%
3,99
39 900 $US
|
10 000
+71.4%
|
3,99
|
39 900 $US
|
|
|
2014-05-27 |
2014-05-27 |
A
Achat
|
FENTON DENNIS M
Administrateur non-exécutif
|
3 000
+30.0%
4,02
12 046 $US
|
3 000
+30.0%
|
4,02
|
12 046 $US
|
|
|
2014-05-28 |
2014-05-23 |
A
Achat
|
Barrett Ronald W
Chief Executive Officer
Administrateur exécutif
|
2 600
+1.5%
3,75
9 745 $US
|
2 600
+1.5%
|
3,75
|
9 745 $US
|
|
|
2014-05-27 |
2014-05-23 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
9 500
+81.2%
3,72
35 354 $US
|
9 500
+81.2%
|
3,72
|
35 354 $US
|
|
|
2014-05-27 |
2014-05-23 |
A
Achat
|
MARIO ERNEST
Administrateur non-exécutif
|
30 000
+55.8%
3,73
111 978 $US
|
30 000
+55.8%
|
3,73
|
111 978 $US
|
|
|
2014-05-27 |
2014-05-22 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
5 500
+88.7%
3,75
20 623 $US
|
5 500
+88.7%
|
3,75
|
20 623 $US
|
|
|
2014-05-16 |
2014-05-15 |
PlS
Vente planifiée
|
BERNS PAUL L
Administrateur non-exécutif
|
2 500
-33.3%
3,66
9 150 $US
|
2 500
-33.3%
|
3,66
|
9 150 $US
|
|
|
2013-06-17 |
2013-06-14 |
V
Vente
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Dirigeant
|
7 500
-31.2%
5,35
40 125 $US
|
7 500
-31.2%
|
5,35
|
40 125 $US
|
|
|
2013-05-23 |
2013-05-22 |
A
Achat
|
MARIO ERNEST
Administrateur non-exécutif
|
20 000
+200.0%
5,49
109 800 $US
|
20 000
+200.0%
|
5,49
|
109 800 $US
|
|
|
2012-08-09 |
2012-08-09 |
A
Achat
|
MARIO ERNEST
Administrateur non-exécutif
|
10 000
+inf%
8,50
84 983 $US
|
10 000
+inf%
|
8,50
|
84 983 $US
|
|
|
2011-12-16 |
2011-12-16 |
A
Achat
|
RIEFLIN WILLIAM JL
Administrateur non-exécutif
|
10 000
+3.7%
3,86
38 580 $US
|
10 000
+3.7%
|
3,86
|
38 580 $US
|
|
|
2011-11-22 |
2011-11-21 |
A
Achat
|
RIEFLIN WILLIAM JL
Administrateur non-exécutif
|
10 000
+3.8%
4,44
44 413 $US
|
10 000
+3.8%
|
4,44
|
44 413 $US
|
|
|
2011-11-09 |
2011-11-07 |
A
Achat
|
RIEFLIN WILLIAM JL
Administrateur non-exécutif
|
5 000
+2.0%
5,49
27 452 $US
|
5 000
+2.0%
|
5,49
|
27 452 $US
|
|
|
2010-11-12 |
2010-11-12 |
A
Achat
|
FENTON DENNIS M
Administrateur non-exécutif
|
300
+30.0%
7,86
2 358 $US
|
300
+30.0%
|
7,86
|
2 358 $US
|
|
|
2010-11-12 |
2010-11-12 |
A
Achat
|
FENTON DENNIS M
Administrateur non-exécutif
|
35
+3.6%
7,87
275 $US
|
35
+3.6%
|
7,87
|
275 $US
|
|
|
2010-11-12 |
2010-11-12 |
A
Achat
|
FENTON DENNIS M
Administrateur non-exécutif
|
100
+11.6%
7,92
792 $US
|
100
+11.6%
|
7,92
|
792 $US
|
|
|
2010-11-12 |
2010-11-12 |
A
Achat
|
FENTON DENNIS M
Administrateur non-exécutif
|
100
+13.1%
7,93
793 $US
|
100
+13.1%
|
7,93
|
793 $US
|
|
|
2010-11-12 |
2010-11-12 |
A
Achat
|
FENTON DENNIS M
Administrateur non-exécutif
|
765
+inf%
7,94
6 071 $US
|
765
+inf%
|
7,94
|
6 071 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
18,47
1 847 $US
|
100
-0.7%
|
18,47
|
1 847 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
18,43
1 843 $US
|
100
-0.7%
|
18,43
|
1 843 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
18,58
1 858 $US
|
100
-0.7%
|
18,58
|
1 858 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
18,61
1 861 $US
|
100
-0.7%
|
18,61
|
1 861 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
18,52
1 852 $US
|
100
-0.7%
|
18,52
|
1 852 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,50
1 850 $US
|
100
-0.6%
|
18,50
|
1 850 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,46
1 846 $US
|
100
-0.6%
|
18,46
|
1 846 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,39
1 839 $US
|
100
-0.6%
|
18,39
|
1 839 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,32
1 832 $US
|
100
-0.6%
|
18,32
|
1 832 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,30
1 830 $US
|
100
-0.6%
|
18,30
|
1 830 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.2%
18,36
3 672 $US
|
200
-1.2%
|
18,36
|
3 672 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.2%
18,49
3 698 $US
|
200
-1.2%
|
18,49
|
3 698 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,57
1 857 $US
|
100
-0.6%
|
18,57
|
1 857 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.2%
18,60
3 720 $US
|
200
-1.2%
|
18,60
|
3 720 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
30
-0.2%
18,79
564 $US
|
30
-0.2%
|
18,79
|
564 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
2
-0.0%
18,80
38 $US
|
2
-0.0%
|
18,80
|
38 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
68
-0.4%
18,81
1 279 $US
|
68
-0.4%
|
18,81
|
1 279 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,68
1 868 $US
|
100
-0.6%
|
18,68
|
1 868 $US
|
|
|
2010-02-04 |
2010-02-01 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,72
1 872 $US
|
100
-0.6%
|
18,72
|
1 872 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
19,20
1 920 $US
|
100
-0.7%
|
19,20
|
1 920 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
19,17
1 917 $US
|
100
-0.7%
|
19,17
|
1 917 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
19,52
1 952 $US
|
100
-0.7%
|
19,52
|
1 952 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
19,36
1 936 $US
|
100
-0.7%
|
19,36
|
1 936 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
32
-0.2%
19,26
616 $US
|
32
-0.2%
|
19,26
|
616 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
268
-1.8%
19,25
5 159 $US
|
268
-1.8%
|
19,25
|
5 159 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.4%
19,28
3 856 $US
|
200
-1.4%
|
19,28
|
3 856 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
19,23
1 923 $US
|
100
-0.7%
|
19,23
|
1 923 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.3%
19,22
3 844 $US
|
200
-1.3%
|
19,22
|
3 844 $US
|
|
|
2010-01-06 |
2010-01-04 |
PlS
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
19,27
1 927 $US
|
100
-0.7%
|
19,27
|
1 927 $US
|
|